PMID- 17987059
OWN - NLM
STAT- MEDLINE
DCOM- 20081008
LR  - 20220311
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 33
IP  - 9
DP  - 2008 Aug
TI  - BDNF levels and genotype are associated with antipsychotic-induced weight gain in 
      patients with chronic schizophrenia.
PG  - 2200-5
AB  - Recent evidence suggests that centrally released brain-derived neurotrophic 
      factor (BDNF) modulates eating behavior and metabolism that is responsible for 
      body weight fluctuation. BDNF also may play an important role in the therapeutic 
      action of antipsychotic medications. We investigated whether the Val66Met 
      polymorphism of the BDNF gene affected weight gain after long-term antipsychotic 
      treatment in schizophrenia. The polymorphism was genotyped in 196 Chinese 
      patients with schizophrenia on long-term antipsychotic medication. Serum BDNF was 
      measured in all patients and 50 normal controls. Mean body mass index (BMI) 
      change was evaluated retrospectively by means of clinical records. The results 
      showed that there was a significant relationship between the three BDNF Val/Met 
      genotypes and mean BMI gain, with genotype having a strong effect on BMI gain in 
      male but not female patients. BDNF levels were significantly lower in patients 
      than normal controls, and negatively correlated with BMI gain in female but not 
      male patients. Our results suggest that variation in the BDNF gene may be a risk 
      factor for weight gain in male patients with schizophrenia on long-term 
      antipsychotic treatment, and decreased BDNF levels may be associated with weight 
      gain in females.
FAU - Zhang, Xiang Yang
AU  - Zhang XY
AD  - Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of 
      Medicine, Houston, TX 77030, USA. xyzhang@bcm.edu
FAU - Zhou, Dong Feng
AU  - Zhou DF
FAU - Wu, Gui Ying
AU  - Wu GY
FAU - Cao, Lian Yuan
AU  - Cao LY
FAU - Tan, Yun Long
AU  - Tan YL
FAU - Haile, Colin N
AU  - Haile CN
FAU - Li, Jun
AU  - Li J
FAU - Lu, Lin
AU  - Lu L
FAU - Kosten, Therese A
AU  - Kosten TA
FAU - Kosten, Thomas R
AU  - Kosten TR
LA  - eng
GR  - K05-DA0454/DA/NIDA NIH HHS/United States
GR  - P50-DA18827/DA/NIDA NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20071107
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Analysis of Variance
MH  - Antipsychotic Agents/*pharmacology/therapeutic use
MH  - Body Mass Index
MH  - Brain-Derived Neurotrophic Factor/blood/*genetics
MH  - Chronic Disease
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - Methionine/genetics
MH  - Polymorphism, Genetic/genetics
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/blood/drug therapy/*genetics/*physiopathology
MH  - Sex Factors
MH  - Valine/genetics
MH  - Weight Gain/*drug effects/genetics
EDAT- 2007/11/08 09:00
MHDA- 2008/10/09 09:00
CRDT- 2007/11/08 09:00
PHST- 2007/11/08 09:00 [pubmed]
PHST- 2008/10/09 09:00 [medline]
PHST- 2007/11/08 09:00 [entrez]
AID - 1301619 [pii]
AID - 10.1038/sj.npp.1301619 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2008 Aug;33(9):2200-5. doi: 10.1038/sj.npp.1301619. Epub 
      2007 Nov 7.